BioPharmSignal logoBioPharmSignal

Biotech News

Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference

Benitec Biopharma (BNTC)Benitec BiopharmaConference / presentation

BNTC (BNTC) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is bntc.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

BNTCBenitec Biopharma2026-03-10 11:00 EST

Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)

BNTCBenitec Biopharma2026-03-09 11:00 EST

Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

ABUSArbutus2025-10-07 12:01 EST

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

ABUSArbutus2025-04-23 06:01 EST

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

PHIOPhio Pharmaceuticals2024-04-30 11:30 EST

Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)

PHIOPhio Pharmaceuticals2023-10-12 15:00 EST

Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

View all latest news

Benitec Biopharma

Benitec Biopharma is a gene-silencing biotechnology company focused on DNA-directed RNA interference and genetic medicine. Its story is built around platform science that aims to durably suppress disease-causing genes.

Recent company news

BNTCBenitec Biopharma2026-05-14 12:00 EST

Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update

BNTCBenitec Biopharma2026-04-28 11:00 EST

Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting

BNTCBenitec Biopharma2026-03-10 11:00 EST

Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)

BNTCBenitec Biopharma2026-03-09 11:00 EST

Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

BNTCBenitec Biopharma2026-02-23 12:00 EST

Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference

Stock data

Close
11.58 USD
Market cap
363.47M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States